Nöroendokrin Tümör Karaciğer Metastazları
Özet
Nöroendokrin tümörler (NET), değişken klinik davranışlar gösteren heterojen bir gruptur ve sıklıkla karaciğere metastaz (NETLM) yaparlar. Tanı anında hastaların önemli bir kısmında karaciğer metastazı mevcut olup, çoğunluğu asemptomatik seyrettiğinden genellikle yaygın hastalık aşamasında fark edilirler. Hastalık yükü; tek lezyondan dissemine multifokal tutuluma kadar üç farklı modelde sınıflandırılır. NETLM tedavisinde küratif veya semptom palyasyonu amaçlı cerrahi rezeksiyon, sağkalım avantajı sağlayan en etkin ve güvenli seçenektir. Başlangıçta cerrahiye uygun olmayan bilobar metastazlı seçilmiş vakalarda portal ven embolizasyonu, iki aşamalı hepatektomi veya ALPPS gibi ileri cerrahi prosedürlerle yeterli karaciğer hacmi sağlanarak rezeksiyon mümkün hale getirilebilir. Cerrahi sınırların %70-90 oranında sitoredüksiyonu semptomatik rahatlama ve sağkalım artışı sağlarken, Milan kriterlerine uyan seçilmiş hastalarda karaciğer transplantasyonu uzun dönem sağkalım avantajı sunar. Cerrahinin uygulanamadığı durumlarda ise tümör hücrelerini yok etmeye ve hormonal semptomları kontrol altına almaya yönelik radyofrekans ablasyon (RFA) ve mikrodalga ablasyon (MVA) gibi ablatif yöntemler ile transarteryal embolizasyon (TAE), TACE, TARE gibi intraarteryal tedaviler ve peptid reseptör radyonüklit tedavisi (PRRT) devreye girer. Multidisipliner yaklaşımla belirlenen bu kombine tedaviler, hastanın performansına, tümörün derecesine ve metastaz yüküne göre optimize edilir.
Neuroendocrine tumors (NET) represent a heterogeneous group exhibiting variable clinical behavior, frequently metastasizing to the liver (NETLM). A significant portion of patients present with liver metastases at diagnosis, which are often detected at an advanced stage because the majority remain asymptomatic. The hepatic tumor burden is classified into three distinct categories ranging from solitary lesions to disseminated multifokal involvement. Surgical resection, performed for curative intent or symptom palliation, remains the most effective and safe treatment modality providing a survival advantage. In select cases with bilobar metastases initially deemed unresectable, advanced surgical interventions such as portal vein embolization, two-stage hepatectomy, or ALPPS can achieve sufficient future liver remnant volume to enable resection. Cytoreductive surgery achieving a 70-90% threshold provides symptomatic relief and prolongs survival, while orthotopic liver transplantation offers long-term survival benefits for highly selected patients meeting the Milan criteria. For unresectable disease, liver-directed non-surgical options including ablative techniques like radiofrequency (RFA) and microwave ablation (MVA) are utilized alongside intra-arterial therapies such as transarterial embolization (TAE), TACE, TARE, and peptide receptor radionuclide therapy (PRRT) to destroy tumor cells and alleviate hormonal symptoms. These therapeutic strategies are optimized through a multidisciplinary approach based on patient performance, tumor grade, and metastatic burden.
Referanslar
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342.
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–959.
Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190(4):432-45.
Yao JC, Hassan M, Phan A, et al. One hundred years after ‘‘carcinoid’’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.
Niederle B, Pape U-F, Costa F, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103(2):125–38
Pavel M, Baudin E, Couvelard A, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76.
Pawa N, Clift AK, Osmani H, et al. Surgical management of patients with neuroendocrine neoplasms of the appendix: appendectomy or more? Neuroendocrinology. 2018;106(3):242-251.
Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer. 2015;121(8):1172-86.
Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29(17):2372-77.
Hofland J, Kaltsas G, de Herder WW. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 2020;41(2):371-403.
Pavel M, O’Toole D, Costa F, et al; Vienna Consensus Conference participants. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172-85.
Frilling A, Li J, Malamutmann E, et al. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009;96(2):175-84.
Nigri G, Petrucciani N, Debs T, et al. Treatment options for PNET liver metastases: a systematic review. World J Surg Oncol. 2018;16(1):142.
Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8-21.
Saxena A, Chua TC, Perera M, et al. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol. 2012;21(3):e131-41.
Kaçmaz E, Heidsma CM, Besselink MGH, et al. Treatment of liver metastases from midgut neuroendocrine tumours: a systematic review and meta-analysis. J Clin Med. 2019;8(3):403.
Yu X, Gu J, Wu H, et al. Resection of liver metastases: a treatment provides a long-term survival benefit for patients with advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Oncol. 2018;2018:6273947.
Kianmanesh R, Sauvanet A, Hentic O, et al. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg. 2008;247(4):659-65.
Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012;255(3):405-14.
Jaeck D, Oussoultzoglou E, Bachellier P, et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg. 2012;255(3):405-14.
Vouche M, Lewandowski RJ, Atassi R, et al. Radiation lobectomy: time dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59(5):1029-36.
Linecker M, Kambakamba P, Raptis DA, et al. ALPPS in neuroendocrine liver metastases not amenable for conventional resection - lessons learned from an interim analysis of the International ALPPS Registry. HPB (Oxford). 2020;22(4):537-44.
Baili E, Tsilimigras DI, Filippou D, et al. Associating liver partition and portal vein ligation for staged hepatectomy in patients with primary liver malignancies: A systematic review of the literature. J BUON. 2019;24(4):1371-81.
Addeo P, Bertin JB, Imperiale A, et al. Outcomes of simultaneous resection of small bowel neuroendocrine tumors with synchronous liver metastases. World J Surg. 2020;44(7):2377-84
Gaujoux S, Gonen M, Tang L, et al. Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann Surg Oncol. 2012;19(13):4270-7.
Schurr PG, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg. 2007;245(2):273-81.
Adam R, de Gramont A, Figueras J, et al; of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015;41(9):729-41.
Gurusamy KS, Pamecha V, Sharma D, et al. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev. 2009;2009(1):CD007118.
McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108(6):1091-6.
Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169(1):36-42; discussion 42-3.
Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29-37.
Chambers AJ, Pasieka JL, Dixon E, et al. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery. 2008;144(4):645-51;
Graff-Baker AN, Sauer DA, Pommier SJ, et al. Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients. Surgery. 2014;156(6):1369-76; discussion 1376-7.
Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163(1):218-25.
Maxwell JE, Sherman SK, O’Dorisio TM, et al. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016;159(1):320-33.
Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17(12):3129-36.
Boudreaux JP, Wang Y-Z, Diebold AE, et al. A single institution’s experience with surgical cytoreduction of stage IV, well differentiated, small bowel neuroendocrine tumors. J Am Coll Surg. 2014;218(4):837-44.
Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16(3):885-94.
Howe JR, Cardona K, Fraker DL, et al. The surgical management of small bowel neuroendocrine tumors: Consensus guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46(6):715-731.
Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society Consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(1):1-33.
Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review. Surgery. 2017;162(3):525-36.
Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol. 2007;47(4):460-6.
Mazzaferro V, Sposito C, Coppa J, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant. 2016;16(10):2892-902.
Chan MY, Ma KW, Chan A. Surgical management of neuroendocrine tumor-associated liver metastases: a review. Gland Surg. 2018;7(1):28-35.
Fan ST, Le Treut YP, Mazzaferro V, et al. Liver transplantation for neuroendocrine tumour liver metastases. HPB. 2015;17(1):23–28.
Gamblin TC, Christians K, Pappas SG. Radiofrequency ablation of neuroendocrine hepatic metastasis. Surg Oncol Clin N Am. 2011;20(2):273-9, vii-viii.
Scott AT, Breheny PJ, Keck KJ, et al. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2019;165(1):166-75.
Mayo SC, de Jong MC, Bloomston M, et al. Surgery versus intraarterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol. 2011;18(13):3657-65.
Mazzaglia PJ, Berber E, Milas M, et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142(1):10-9.
Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol2008 Oct;15(10):2757-64
Rhim H, Lim HK. Radiofrequency ablation of hepatocellular carcinoma: pros and cons. Gut Liver. 2010;4 Suppl 1(Suppl 1):S113-8
Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: Current status. World J Radiol. 2010 Nov 28;2(11):417-24.
Berber E, Tsinberg M, Tellioglu G, et al. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg. 2008;12(11):1967-72.
Landry CS, Scoggins CR, McMasters KM, et al. Management of hepatic metastasis of gastrointestinal carcinoid tumors. J Surg Oncol. 2008;97(3):253-8.
Akyildiz HY, Mitchell J, Milas M, et al. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery. 2010;148(6):1288-93
Urbonas T, Anderson EM, Gordon-Weeks AN, et al. Factors predicting ablation site recurrence following percutaneous microwave ablation of colorectal hepatic metastases. HPB (Oxford). 2019;21(9):1175-1184.
Perrodin SF, Renzulli MM, Maurer MH, et al. Can microwave ablation be an alternative to resection for the treatment of neuroendocrine liver metastases? Endocr Pract. 2020;26(4):378-387.
Cannon R, Ellis S, Hayes D, Narayanan G, Martin RCG. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol.?????????
Kennedy A, Bester L, Salem R, et al. NET-Liver-Metastases Consensus Conference. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver- Metastases Consensus Conference. HPB (Oxford). 2015;17(1):29-37.
Bhagat N, Reyes DK, Lin M, et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol. 2013;36(2):449-59.
de Baere T, Deschamps F, Tselikas L, et al. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol. 2015;172(4):R151-66.
Zappa M, Abdel-Rehim M, Hentic O, et al. Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. Target Oncol. 2012;7(2):107-16.
Del Prete M, Fiore F, Modica R, et al; Multidisciplinary Group for NeuroEndocrine Tumors of Naples. Hepatic arterial embolization in patients with neuroendocrine tumors. J Exp Clin Cancer Res. 2014;33(1):43.
Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol Northwood Lond Engl. 2011;28 Suppl 1:S286-90.
Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol. 2007;188(5):1201-7.
Mayo SC, de Jong MC, Bloomston M, et al. Surgery versus intraarterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol. 2011;18(13):3657-65.
van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ. GEPNETs update: Radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol. 20015;172(1):R1-8.
Hicks RJ, Kwekkeboom DJ, Krenning E, et al; Antibes Consensus Conference participants. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105:295-309.
Strosberg J, El-Haddad G, Wolin E, et al; NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125-135.
Bertani E, Fazio N, Radice D, et al. Resection of the primary tumor followed by peptide receptor radionuclide therapy as upfront strategy for the treatment of G1-G2 pancreatic neuroendocrine tumors with unresectable liver metastases. Ann Surg Oncol. 2016;23:981-989.
Ezziddin S, Meyer C, Kahancova S, et al. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med. 2012;53:1663-1669.
Kesavan M, Turner JH. Myelotoxicity of peptide receptor radionuclide therapy of neuroendocrine tumors: a decade of experience. Cancer Biother Radiopharm 2016;31:189-198.
